1092484-56-4

White Solid

Antilipemic. It is a lipid regulating drug. Increases high density lipoprotein levels by reducing cholesteryl ester transfer protein expresion.

Fenofibrate-d₆ is intended for use as an internal standard for the quantification of fenofibrate by GC- or LC-MS. Fenofibrate is an agonist of peroxisome proliferator-activated receptor α (PPARα) with EC₅₀ values of 18 and 30 μM for mouse and human receptors, respectively, in a transactivation assay. It is selective for PPARα over PPARγ (EC₅₀s = 300 and 200 μM for mouse and human receptors, respectively) and lacks activity at mouse and human PPARδ at a concentration of 100 μM. In vivo, fenofibrate (50-100 mg/kg) reduces plasma levels of triglycerides, C-reactive protein, and malondialdehyde (MDA) in mice with fructose-induced hypertriglycemia in a dose-dependent manner. It decreases glomerular and tubular atrophy and necrosis induced by cisplatin in rat kidney when administered at a dose of 100 mg/kg. Fenofibrate also reduces the number of pulmonary lesions induced by 4-nitroquinoline 1-oxide (4-NQO) in lung of Tsumura Suzuki obese diabetic (TSOD) mice.

CYP2; CYP3

Store at -20°C

[1] TIMOTHY M. WILLSON. The PPARs: From Orphan Receptors to Drug Discovery?[J]. Journal of Medicinal Chemistry, 2000, 43 4: 527-550. DOI: 10.1021/jm990554g
[2] BING SUN. Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia.[J]. Lipids in Health and Disease, 2015, 14: 27. DOI: 10.1186/s12944-015-0032-3
[3] M. HELMY M E M M Helmy. Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs[J]. PLoS ONE, 2015, 10 1. DOI: 10.1371/journal.pone.0142303
[4] TOSHIYA KUNO. The peroxisome proliferator-activated receptor (PPAR) α agonist fenofibrate suppresses chemically induced lung alveolar proliferative lesions in male obese hyperlipidemic mice.[J]. International Journal of Molecular Sciences, 2014, 15 5: 9160-9172. DOI: 10.3390/ijms15059160